Royalties and Other Compensation Sample Clauses

Royalties and Other Compensation. (a) Warner will pay LeukoSite one of the following royalties on worldwide Net Sales of Warner Products, whichever is applicable: (i) If LeukoSite does not timely elect to pursue marketing rights to the Development Candidate under Section 4.1 or if a Warner-LeukoSite Product becomes a Warner Product prior to LeukoSite paying its designated share of Development Costs under Section 4.2 up to and including acceptance by the FDA of the relevant IND, the applicable royalty rate will be *** of worldwide Net Sales. (ii) If LeukoSite pays its designated share of Development Costs under Section 4.2 up to and including the acceptance by the FDA of the relevant IND, but thereafter revokes its marketing rights such that the Warner-LeukoSite Product becomes a Warner Product, the applicable royalty rate will be ******************************************************************* ******************************************************************* ******************************************************************* (iii) If LeukoSite pays its designated share of Development Costs under Section 4.2 up to and including completion of all Phase II clinical studies reasonably deemed necessary by the Management Committee for regulatory approval to market the Product in the United States of America, but thereafter revokes its marketing rights such that the Warner-LeukoSite Product becomes a Warner Product, the applicable royalty rate will be ******************************************************************* ******************************************************************* ******************************************************************* (iv) For Warner Products, which become Warner Products under Section 1.4(b) and/or Section 1.4(c), the applicable royalty will be ****** * Confidential treatment requested: material has been omitted and filed separately with the Commission. 25 25 ************************************************************************* ************************************************************************* (b) Warner will pay LeukoSite the following royalties on Net Sales of all Warner-LeukoSite Products sold outside of the Designated Co-Promotion Countries for which LeukoSite has paid its designated share of Development Costs under Section 4.2 up to and including NDA approval in the United States: ************************************************************************* ************************************************************************* (c) LeukoSite w...
Sample 1
AutoNDA by SimpleDocs
Royalties and Other Compensation. (a) In the event LeukoSite declines to pay its share of Development Costs, as provided in Section 4.1, Warner will pay LeukoSite one of the following royalties on worldwide Net Sales of Warner Products: ** of worldwide, annual Net Sales up to ***********; *** of worldwide, annual Net Sales from above ********************** and *** of worldwide, annual Net Sales above ***********. (b) If LeukoSite pays its designated share of Development Costs under Section 4.1, LeukoSite will receive its Share of Profit for such Warner-LeukoSite Product. (c) LeukoSite will pay Warner royalties on worldwide Net Sales of LeukoSite Products of **. (d) The royalties set forth in this Section will be payable on a Product by Product and country by country basis for a period of ten (10) years from first commercial sale in a country as part of nationwide introduction of the Product. If at the expiration of such ten (10) year period, a Product(s) is sold in a country(ies) and such Product(s) where manufactured, used or sold infringes a Patent Right, then the royalty shall continue with respect to such Product(s) in such country(ies) until expiration of such Patent Right. (e) As used herein, "Annual Net Sales" shall mean Net Sales in a calendar year.
Sample 1
Royalties and Other Compensation. (a) KHK shall pay to LKS royalties on the annual NET SALES of PRODUCTS sold by KHK, its AFFILIATES and SUBLICENSEES in the TERRITORY as follows: * of NET SALES up to *, * of NET SALES over * and less than * and * of NET SALES * or over. (b) Such royalties shall be paid as set forth above by KHK, on a country by country, PRODUCT by PRODUCT, basis for a period of at least twelve (12) years in each country of the TERRITORY from the date of FIRST COMMERCIAL SALE by KHK, its AFFILIATES and SUBLICENSEES of such PRODUCT in each such country and thereafter such PRODUCT is covered by a VALID CLAIM of a PATENT RIGHT, such royalties shall be payable until the last to expire PATENT RIGHT in such country. (a) Subject to Section 2.2(d), KHK shall pay the following amounts upon the occurrence of the following milestone events, which may be achieved by KHK through a SUBLICENSEE or AFFILIATE. (i) upon selection of a DEVELOPMENT CANDIDATE as set forth in the Agreement. In addition, in the event KHK elects to pursue two (2) TARGETS with LKS, KHK will pay to LKS * * Confidential treatment requested: material has been omitted and filed separately with the Commission. 29 -29- * upon selection of the first DEVELOPMENT CANDIDATE resulting from the second TARGET chemokine receptor program. (ii) upon initiation of human clinical trials of a COMPOUND (from each chemokine receptor TARGET program). (iii) upon initiation of Phase III clinical trials of a COMPOUND (from each chemokine receptor TARGET program). (iv) upon issue of first market approval of a COMPOUND (from each chemokine receptor TARGET program) (b) Should a COMPOUND and/or PRODUCT replace another compound and/or PRODUCT before such compound and/or PRODUCT reaches the market, it shall, for the purpose of milestones, enter at the next payable milestone. (a) In the event that royalties are required to be paid by KHK to a THIRD PARTY who is not an AFFILIATE of KHK in order for KHK to make, use and sell PRODUCT without infringing such THIRD PARTY'S patents and for which royalties are also due to LKS pursuant to Paragraph 7.1 (such royalties to such THIRD PARTY are hereinafter "Other Royalties"), then the royalties to be paid to LKS by KHK pursuant to Paragraph 7.1 shall be reduced by one-half of the amount of such Other Royalties. but in no event shall any royalties payable under Paragraph 7.1 be reduced by more than * of NET SALES. As an example, if the royalty due LKS is * and Other Royalties * Confidential treatment request...
Sample 1
Royalties and Other Compensation. (A) MEDIMMUNE shall pay to UNIVERSITY: a royalty of (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) of the NET SALES of PRODUCTS which are sold by MEDIMMUNE or its AFFILIATES and which are covered by a VALID CLAIM of any PATENT RIGHT licensed to LICENSEE hereunder in the country where sold; or (ii) a royalty of the lesser of (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) of the running royalty received by LICENSEE from its SUBLICENSEES for the sale of PRODUCTS or (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) of the NET SALES of PRODUCT sold by the SUBLICENSEE. (B) In the event that MEDIMMUNE'S license is converted to a non- exclusive license pursuant to Section 2.4(c), the royalties under Paragraph 5.1 (A) shall be reduced by (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). (C) In the event that a PRODUCT includes both component(s) covered by a VALID CLAIM of a PATENT RIGHT ("Patented Component(s)") and a component which is therapeutically active and such component is not covered by a VALID CLAIM of a PATENT RIGHT ("Unpatented Component(s) (s)") (such PRODUCT being a "Combined Product"), then NET SALES shall be the amount which is normally received by MEDIMMUNE or its AFFILIATES from the sale of the Patented Component(s) in an arm's length transaction with an unaffiliated third party. If the Patented Component (s) are not sold separately, then NET SALES upon which a royalty is paid shall be the NET SALES of the Combined Product multiplied by a fraction, the numerator of which is the number of Patented Components in the Combined Product and the denominator of which is the total number of therapeutically active Components (Patented) Components plus Unpatented Components) in the Combined Product. (D) In the event that royalties are to be paid by MEDIMMUNE to a party who is not an AFFILIATE of MEDIMMUNE for PRODUCT for which royalties are also due to UNIVERSITY pursuant to Paragraph 5.1 (such royalties to such party are hereinafter "Other Royalties"), then the royalties to be paid to UNIVERSITY by MEDIMMUNE pursuant to Paragraph 5.1 (A) or (B) shall be reduced by (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) of the amount of such Other Royalties, but in no event shall any royalities payable under Paragraph 5.1 be reduced by more than (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). (a) Upon execution of this Agreement, MEDIMMUNE shall pay UNIVERSITY a license fee of (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). (b) MEDIMMUNE shall also pay the following amounts within thirty (30)...
Sample 1
Royalties and Other Compensation. (A) LICENSEE shall pay to LICENSOR: (i) a royalty of [Information omitted and filed separately with the Commission under Rule 24b-2.] of the NET SALES of PRODUCTS which are manufactured or sold by LICENSEE or its AFFILIATES and licensed to LICENSEE hereunder; or (ii) a royalty based on the royalties received by LICENSEE from its SUBLICENSEES from the manufacture, use or sale of PRODUCTS as follows: (a) [Information omitted and filed separately with the Commission under Rule 24b-2.] of such royalties received by LICENSEE from a SUBLICENSEE during the [Information omitted and filed separately with the Commission under Rule 24b-2.] years of sales of PRODUCT by such SUBLICENSEE; (b) [Information omitted and filed separately with the Commission under Rule 24b-2.] of such royalties received by LICENSEE from a SUBLICENSEE during the next [Information omitted and filed separately with the Commission under Rule 24b-2.] years of sales of PRODUCT by such SUBLICENSEE; (c) [Information omitted and filed separately with the Commission under Rule 24b-2.] of such royalties received by LICENSEE from a SUBLICENSEE from sales of PRODUCT by such SUBLICENSEE for each year thereafter. (B) LICENSEE shall also pay or provide to LICENSOR the following: (i) A license fee of [Information omitted and filed separately with the Commission under Rule 24b-2.] payable upon the EFFECTIVE DATE. This amount shall not be refundable or creditable. (ii) [***] of all other revenues (in cash or in kind) received by LICENSEE from a SUBLICENSEE in consideration of the granting of sublicense rights to such SUBLICENSEE. Revenues for this purpose shall not include either (a) research and development funding at LICENSEE's cost, or (b) purchases of equity in LICENSEE, except to the extent that such purchases are made in excess of fair market value. (iii) Nonrefundable and non-creditable milestones payable on completion of the milestone as follows: (a) [***] (b) [***] (c) [***] (d) [***] (C) Beginning on the earlier of [***] or [***], LICENSEE shall pay LICENSOR minimum royalties of [***] per year, which payment shall be fully creditable against future earned royalties at the rate of [***] per earned royalty dollar. Such minimum royalties shall increase to [***] per year effective the earlier of [***] * [Information omitted and filed separately with the Commission under Rule 24b-2.] [Information omitted and filed separately with the Commission under Rule 24b-2.] and shall also be fully creditable against...
Sample 1
Royalties and Other Compensation. (a) Warner will pay LeukoSite one of the following royalties on worldwide Net Sales of Warner Products, whichever is applicable: (i) If LeukoSite does not timely elect to pursue marketing rights to the Development Candidate under Section 4.1 or if a Warner-LeukoSite Product becomes a Warner Product prior to LeukoSite paying its designated share of Development Costs under Section 4.2 up to and including acceptance by the FDA of the relevant IND, the applicable royalty rate will be * of worldwide Net Sales. (ii) If LeukoSite pays its designated share of Development Costs under Section 4.2 up to and including the acceptance by the FDA of the relevant IND, but thereafter revokes its marketing rights such that the Warner-LeukoSite Product becomes a Warner Product, the applicable royalty rate will be * of worldwide, annual Net Sales up to $100 Million; * of worldwide, annual Net Sales from above $100 Million to $250 Million and * of worldwide, annual Net Sales above $250 Million. (iii) If LeukoSite pays its designated share of Development Costs under Section 4.2 up to and including completion of all Phase II clinical studies reasonably deemed necessary by the Management Committee for regulatory approval to market the Product in the United States of America, but thereafter revokes its marketing rights such that the Warner-LeukoSite Product becomes a Warner Product, the applicable royalty rate will be * of worldwide, annual Net Sales up to $100 Million; * of worldwide, annual Net Sales from above $100 Million to $250 Million and * of worldwide, annual Net Sales above $250 Million. (iv) For Warner Products, which become Warner Products under Section 1.4(b) and/or Section 1.4(c), the applicable royalty will be * of * Confidential treatment requested: material has been omitted and filed separately with the Commission. 25 25 worldwide, annual Net Sales up to $100 Million and * of worldwide, annual Net Sales above $100 Million. (b) Warner will pay LeukoSite the following royalties on Net Sales of all Warner-LeukoSite Products sold outside of the Designated Co-Promotion Countries for which LeukoSite has paid its designated share of Development Costs under Section 4.2 up to and including NDA approval in the United States: * of such annual Net Sales up to $100 Million and * of such annual Net Sales above $100 Million. (c) LeukoSite will pay Warner one of the following royalties on worldwide Net Sales of LeukoSite Products, whichever is applicable: (i) The applicable royal...
Sample 1
Royalties and Other Compensation 
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs

Related to Royalties and Other Compensation

  • Salary and Other Compensation As compensation for the services to be rendered by the Employee to the Company pursuant to this Agreement, the Employee shall be paid the following compensation and other benefits:

  • Royalties and Other Payments 5.1 For the rights, privileges and exclusive licenses granted hereunder, Licensee shall pay to CMCC the following amounts in the manner hereinafter provided until the end of the term of the last to expire Licensed Patent Right, unless this Agreement shall be sooner terminated as hereinafter provided: (a) A license issue fee of [**] Dollars ($[**]), which license issue fee shall be deemed earned on the date of the execution of this Agreement. (b) A License Maintenance Fee of [**] Dollars ($[**]),[**] Dollars ($[**]) of which shall be payable within [**] days of the first anniversary of the date of execution of this License Agreement and, [**] Dollars ($[**]) of which shall be payable [**] thereafter. (c) Licensee shall make the following milestone payments to CMCC upon the completion of the following events by Licensee (“Licensee Milestones”): (i) Payment of [**] Dollars ($[**]) upon [**] by Licensee, but not more than one payment shall be required for each Licensed Product or Licensed Process in the event that more than one [**] is required for the same Licensed Product or Licensed Process. (ii) Payment of Two Hundred Thousand Dollars ($[**]) upon [**] with respect to a Licensed Product or a Licensed Process. (iii) The Licensee Milestones will be creditable toward running royalties due CMCC for Net Sales by Licensee, up to, and no more than, [**]% of the Net Sales due in any given payment period. (iv) Notwithstanding anything to the contrary herein, it is understood by the parties that if Licensee ceases to develop a Licensed Product or Licensed Process prior to the payment of all milestones specified in this paragraph 5.1 (such Licensed Product being referred to as a “Canceled Product”) and Licensee decides to develop a different Licensed Product or Licensed Process for the same labeled indication as the Canceled Product, then Licensee shall, with respect to such other Licensed Product or Licensed Process, be obligated to pay only that/those milestone payment(s) which were not made with respect to the Canceled Product; provided however, that if Licensee does at some time in the future develop such canceled product, then appropriate and prompt adjustment with respect to milestone payments shall be made hereunder. (d) Running royalties on a country-by-country basis in an amount equal to [**] percent ([**]%) of Net Sales by Licensee or an Affiliate of Licensed Products or Licensed Processes derived from a new chemical entity disclosed by CMCC to Licensee and which, but for this Agreement would infringe a Valid Claim of the Licensed Patent Rights. Running royalties on a country-by-country basis in an amount equal to [**] percent ([**]%) of Net Sales by Licensee or an Affiliate of Licensed Products or Licensed Processes derived from a new chemical entity discovered by Licensee or its Affiliate and which, but for this Agreement would infringe a Valid Claim of the Licensed Patent Rights. 5.2 In the event Licensee or its Affiliate has granted sublicenses under this Agreement, Licensee or its Affiliate will pay CMCC [**] percent ([**]%) of Gross Compensation received by Licensee or its Affiliate from said Sublicensees on a country-by-country basis for Licensed Products or Licensed Processes derived from a new chemical entity disclosed by CMCC to Licensee or its Affiliate which, but for this Agreement would infringe a Valid Claim of the Licensed Patent Rights in the country, and [**] percent ([**]%) of Gross Compensation received by Licensee or its Affiliate from said Sublicensees for Licensed Products or Licensed Processes derived from a new chemical entity discovered by Licensee, its Affiliate or Sublicensee, and which, but for this Agreement would infringe a Valid Claim of the Licensed Patent Rights in the country. 5.3 No multiple royalties shall be payable because any Licensed Product or Licensed Process, its manufacture, use, lease or sale which, but for this Agreement would infringe a Valid Claim of more than one patent licensed under this Agreement. 5.4 To the extent that Licensee or its Affiliates obtains subsequent to the date of this Agreement licenses to third party patents or other intellectual property that it or they reasonably believes are necessary to produce or sell Licensed Products or Licensed Processes, Licensee may deduct from the running royalty on Net Sales due to CMCC [**] percent [**]%) of the Net Sales as appropriate on a country by country basis due in respect of such third party patents or intellectual property, but only up to an amount equal to [**] percent ([**]%) of the Net Sales or share of Gross Compensation due hereunder for the same payment period. 5.5 For purposes of calculating royalties, in the event that a Licensed Product or Licensed Process includes both component(s) which, but for this Agreement would infringe a Valid Claim of the Licensed Patent Rights (“Patented Component”) and a component which is diagnostically useable or therapeutically active alone or in a combination which does not require the Patented Component, and such component is not covered by a Valid Claim of a Licensed Patent Right (“Unpatented Component”), then Net Sales of the Combination Product or Combination Process shall be calculated using one of the following methods; provided that in no event shall royalties payable to CMCC hereunder be reduced to less than fifty percent (50%) of those otherwise due hereunder: (a) By multiplying the Net Sales of the Combination Product or Combination Process during the applicable royalty accounting period (“accounting period”) by a fraction, the numerator of which is the aggregate gross selling price of the Patented Component(s) contained in the Combination Product or Combination Process if sold separately, and the denominator of which is the sum of the gross selling price of both the Patented Component(s) and the Unpatented Component(s) contained in the Combination Product or Combination Process if sold separately; or (b) In the event that no such separate sales are made of the Patented Component(s) or the Unpatented Components during the applicable accounting period, Net Sales for purposes of determining royalties payable hereunder shall be calculated by multiplying the Net Sales of the Combination Product or Combination Process by a fraction, the numerator of which is the fully allocated production cost of the Patented Component(s) and the denominator of which is the sum of the fully allocated production costs of the Patented Component(s) and the Unpatented Component(s) contained in the Combination Product or Combination Process. Such fully allocated costs shall be determined by using Licensee’s standard accounting procedures, which procedures must conform to standard cost accounting procedures. 5.6 Royalty payments shall be paid in United States dollars in Boston, Massachusetts, or at such other place as CMCC may reasonably designate consistent with the laws and regulations controlling in any foreign country. If the currency conversion shall be required in connection with the payments of royalties or other amounts hereunder, the conversion shall be made by using the exchange rate prevailing at the Bank of Boston on the last business day of the calendar quarterly reporting period to which such royalty payments relate. 5.7 The royalty payments set forth in this Agreement shall, if overdue, bear interest until payment at a per annum rate of four percent (4%) above the prime rate in effect at the Bank of Boston on the due date. The payment of such interest shall not foreclose CMCC from exercising any other rights it may have as a consequence of the lateness of any payment.

  • Servicing and Other Compensation The Servicer, as compensation for its activities hereunder, shall be entitled to receive, on or prior to each Distribution Date, the amounts provided for as the Servicing Fee and as reimbursement for Nonrecoverable Advances, Servicing Advances and reimbursement for Advances, all as specified by Section 5.09. The amount of compensation or reimbursement provided for shall be accounted for on a Mortgage Loan-by-Mortgage Loan basis. Additional servicing compensation in the form of assumption fees, prepayment fees and late payment charges shall be retained by the Servicer, to the extent permitted by applicable law. The Servicer shall be required to pay all expenses incurred by it in connection with its servicing activities hereunder (including the fees and expenses of the Trustee and any Sub-Servicer) and shall not be entitled to reimbursement therefor except as specifically provided in Sections 5.09 and 5.21.

  • COMPENSATION AND OTHER FEES As compensation for the services provided by Xxxxxx xxxxxxxxx, the Company agrees to pay to Xxxxxx: (A) The fees set forth below with respect to the Placement: 1. A cash fee payable immediately upon the closing of the Placement and equal to 6% of the aggregate gross proceeds raised in the Placement. Additionally, a cash fee payable within 48 hours of (but only in the event of) the receipt by the Company within 12 months of the Closing Date of any proceeds from the exercise of the Warrants sold in the Placement that are solicited by the Placement Agent and otherwise in compliance with Financial Industry Regulatory Authority (“FINRA”) Rule 5110 equal to 5% of the aggregate cash exercise price received by the Company upon such exercise, if any (the “Warrant Solicitation Fee”), provided, however, the Warrant Solicitation Fee shall be reduced (before any reduction to the Xxxxxx Warrants described in the last sentence of Section A.2 below or any reduction to the expense reimbursement to Xxxxxx in Section B below) to the extent (and only to the extent) that Xxxxxx’x aggregate compensation for the Placement, as determined under FINRA Rule 5110, would otherwise exceed 8%. Such determination of the actual Warrant Solicitation Fee shall be made promptly following completion of the Placement and communicated in writing to the Company. 2. Such number of warrants (the “Xxxxxx Warrants”) to be issued to Xxxxxx or its designees at the Closing to purchase shares of Common Stock equal to 5% of the aggregate number of Shares sold in the Placement. The Xxxxxx Warrants shall have the same terms as the Warrants (if any) issued to the Purchasers in the Placement except that the exercise price shall be at least 125% of the public offering price per share, but in any event not less than the Warrant exercise price, and the expiration date shall be November 27, 2012. The Xxxxxx Warrants shall not have antidilution protections or be transferable for six months from the date of the Offering except as permitted by FINRA Rule 5110, and further, the number of Shares underlying the Xxxxxx Warrants shall be reduced if necessary to comply with FINRA rules or regulations. Such determination of the actual number of Shares underlying the Xxxxxx Warrants shall be made promptly following completion of the Placement and communicated in writing to the Company. (B) The Company also agrees to reimburse Xxxxxx’x expenses (with supporting invoices/receipts) up to a maximum of 0.8% of the aggregate gross proceeds raised in the placement, but in no event more than $30,000 and only in the event the Placement has been consummated. If payable, such reimbursement shall be paid immediately upon the closing of the Placement.

  • Compensation and Other Benefits Subject to the provisions of this Agreement, the Company shall pay and provide the following compensation and other benefits to the Executive during the Term as compensation for services rendered hereunder:

  • Rent and Other Payments This paragraph contains detailed commercial terms. ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ .

  • No Other Compensation Each Party hereby agrees that the terms of this Agreement fully define all consideration, compensation and benefits, monetary or otherwise, to be paid, granted or delivered by one Party to the other Party in connection with the transactions contemplated herein. Neither Party previously has paid or entered into any other commitment to pay, whether orally or in writing, any of the other Party’s employees, directly or indirectly, any consideration, compensation or benefits, monetary or otherwise, in connection with the transaction contemplated herein.

  • Improper and Other Payments (a) Neither the Company, any director, officer, employee thereof, nor any agent or representative of the Company nor any person acting on behalf of any of them, has made, paid or received any unlawful bribes, kickbacks or other similar payments to or from any person or authority, (b) no contributions have been made, directly or indirectly, by the Company to a domestic or foreign political party or candidate; and (c) the internal accounting controls of the Company are believed by the Company’s management to be adequate to detect any of the foregoing under current circumstances.

  • Payment of Employment Taxes and Other Expenses Should City, in its discretion, or a relevant taxing authority such as the Internal Revenue Service or the State Employment Development Division, or both, determine that Contractor is an employee for purposes of collection of any employment taxes, the amounts payable under this Agreement shall be reduced by amounts equal to both the employee and employer portions of the tax due (and offsetting any credits for amounts already paid by Contractor which can be applied against this liability). City shall then forward those amounts to the relevant taxing authority. Should a relevant taxing authority determine a liability for past services performed by Contractor for City, upon notification of such fact by City, Contractor shall promptly remit such amount due or arrange with City to have the amount due withheld from future payments to Contractor under this Agreement (again, offsetting any amounts already paid by Contractor which can be applied as a credit against such liability). A determination of employment status pursuant to the preceding two paragraphs shall be solely for the purposes of the particular tax in question, and for all other purposes of this Agreement, Contractor shall not be considered an employee of City. Notwithstanding the foregoing, Contractor agrees to indemnify and save harmless City and its officers, agents and employees from, and, if requested, shall defend them against any and all claims, losses, costs, damages, and expenses, including attorneys’ fees, arising from this section.

  • Vacation and Other Leave During the Period of Employment, the Executive shall accrue and be entitled to take paid vacation in accordance with the Company’s vacation policies in effect from time to time, including the Company’s policies regarding vacation accruals; provided that the Executive’s rate of vacation accrual during the Period of Employment shall be no less than three (3) weeks per year. The Executive shall also be entitled to all other holiday and leave pay generally available to other executives of the Company.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!